Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
Xiaomeng YueBin HuangAna L HincapiePatricia R WigleTingting QiuYuxiang LiEsi M MorganJeff J GuoPublished in: Paediatric drugs (2021)
There was a substantial increase in the proportion of patients receiving the combination of methotrexate and adalimumab among patients receiving combination therapy. Adalimumab overtook etanercept as the most frequently prescribed bDMARD. Multiple factors affect the time to biologic initiation, including the number of joints with limited range of motion, ESR, and JIA category.
Keyphrases
- juvenile idiopathic arthritis
- combination therapy
- rheumatoid arthritis
- disease activity
- primary care
- young adults
- rheumatoid arthritis patients
- high dose
- ankylosing spondylitis
- estrogen receptor
- systemic lupus erythematosus
- emergency department
- high speed
- mass spectrometry
- bone marrow
- high resolution
- smoking cessation
- electronic health record